The AACU Supports Federal Funding for the Kidney Cancer Research Program (KCRP)

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

Trajectory inference analysis pointed to SIX2+CITED1+ as the nephrogenic cancer stem cells at the origin of Wilms tumor.

Adding cabozantinib to nivolumab/ipilimumab improved PFS in frontline renal cell carcinoma; however, there was increased toxicity with the triplet, including more adverse event–related discontinuations.

The phase 3 RENOTORCH study is comparing the combination of the PD1-inhibitor toripalimab and axitinib with single-agent sunitinib in patients with renal cell carcinoma.

The bill, H.R. 2474, would tie the Medicare physician fee schedule to the Medicare Economic Index (MEI), something the AACU and the AMA have long supported

The AACU is in favor of this effort in order provide an accurate update of the Medicare Economic Index